| Autor: |
Pascual-Morena C; Health and Social Research Center, Universidad de Castilla-La Mancha, Cuenca, Spain.; Facultad de Enfermería de Albacete, Universidad de Castilla-La Mancha, Albacete, Spain., Martínez-Vizcaíno V; Health and Social Research Center, Universidad de Castilla-La Mancha, Cuenca, Spain.; Facultad de Ciencias de la Salud, Universidad Autónoma de Chile, Talca, Chile., Cavero-Redondo I; Facultad de Ciencias de la Salud, Universidad Autónoma de Chile, Talca, Chile.; CarVasCare Research Group, Facultad de Enfermería de Cuenca, Universidad de Castilla-La Mancha, Cuenca, Spain., Álvarez-Bueno C; Health and Social Research Center, Universidad de Castilla-La Mancha, Cuenca, Spain.; Universidad Politécnica y Artística del Paraguay, Asunción, Paraguay., Lucerón-Lucas-Torres M; Health and Social Research Center, Universidad de Castilla-La Mancha, Cuenca, Spain., Saz-Lara A; CarVasCare Research Group, Facultad de Enfermería de Cuenca, Universidad de Castilla-La Mancha, Cuenca, Spain., Martínez-García I; CarVasCare Research Group, Facultad de Enfermería de Cuenca, Universidad de Castilla-La Mancha, Cuenca, Spain. |
| Abstrakt: |
There is a high prevalence of neuropsychiatric disorders in myotonic dystrophy types 1 and 2 (DM1 and DM2), including autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in DM1, and depression and anxiety in both DMs. The aim of this systematic review and meta-analysis was to estimate the prevalence of ASD, ADHD, depression and anxiety in the population with DM, and their association with disease onset. A systematic search of Medline, Scopus, Web of Science, and the Cochrane Library was conducted from inception to November 2023. Observational studies estimating the prevalence of these disorders in DM1 or DM2 were included. A meta-analysis of the prevalence of these disorders and an association study with disease onset by prevalence ratio meta-analysis were performed. Thirty-eight studies were included. In DM1, the prevalence of ASD was 14%, with congenital onset being 79% more common than juvenile onset, while the prevalence of ADHD was 21%, with no difference between congenital and juvenile onset, and the prevalence of depression and anxiety were 14% and 16%. Depression was more common in the adult onset. Finally, the prevalence of depression in DM2 was 16%. A higher prevalence of neuropsychiatric disorders is observed in individuals with DM1 and DM2 than in the general population. Therefore, actively screening for congenital and juvenile neurodevelopmental disorders in DM1 and emotional disorders in DM1 and DM2 may improve the quality of life of those affected. |
